RatcliffeP.J., EbertB.L., FergusonD.J.P.Regulation of the erythropoietin gene.Nephrol Dial Transplant1995; 10(Suppl 2): 18–27.
2.
JolliffeL.K., MiddletonS.A., BarboneF.P.Erythropoietin receptor: Application in drug development.Nephrol Dial Transplant1995; 10(Suppl 2): 28–34.
3.
EschbachJ.W.The future of r-HuEPO.Nephrol Dial Transplant1995; 10(Suppl 2): 96–109.
4.
GeerlingsW., MorrisR.W., BrunnerF.P.Factors influencing anaemia in dialysis patients. A special survey by the EDTA-ERARegistryNephrolDial Transplant1993; 8: 585–9.
5.
ChandraM., ClemonsG.K., McVicarM.Serum erythropoietin levels and hematocrit in end-stage renal disease: Influence of the mode of dialysis.Am J Kidney Dis1988; 12: 208–13.
6.
ZappacostaA.R., CaroJ., ErslevA.Normalization of hematocrit in patients with end-stage renal disease on continuous ambulatory peritoneal dialysis.Am J Med1982; 72: 53–7.
7.
McGonigleR.J.S., HusseriF., WallinJ.D., FischerJ.W.Hemodialysis and continuous ambulatory peritoneal dialysis effects on erythropoiesis in renal failure.Kidney Int1984; 25: 430–6.
8.
KorbetS.M.Anemia and erythropoietin in hemodialysis and continuous ambulatory peritoneal dialysis.Kidney Int1993; 43: (Suppl 40): S111–119.
USRDS 1994 Annual Data Report.Erythropoietin use in dialysis patients.Am J Kidney Dis1994; 24(Suppl 2): S69–73.
11.
ZachéeP., Van RompuyW.Correcting the anaemia of end-stage renal failure with recombinant human erythropoietin (r-HuEPO): The Benelux experience.Erythropoiesis: New Dimensions in the Treatment of Anaemia1994; 5: 51–7.
12.
CotesP.M., PippardM.J., ReidC.D.L.Characterization of the anemia of chronic renal failure and the mode of its correction by a preparation of human erythropoietin (r-HuEPO). An investigation of the pharmaco-kinetics of intravenous erythropoietin and its effects on erythrokinetics.Q J Med1989; 70: 113–37.
13.
FlahartyK.K., CaroJ., ErslevA.Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy men.Clin Pharmacol Ther1990; 47: 557–64.
14.
LuiS.F., ChungW.W.M., LeungC.B.Pharmacokinetic and pharmacodynamics of subcutaneous and intraperitoneal administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis.Clin Nephrol1990; 33: 47–51.
15.
MacdougallI.C., RobertsD.E., NeubertP.Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis.Lancet1989; 1: 425–7.
16.
McMahonF.G., VargasR., RyanM.Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers.Blood1990; 76: 1718–22.
17.
NielsenO.J.Pharmacokinetics of recombinant human erythropoietin in chronic haemodialysis patients.Pharmacol Toxicol1990; 66: 83–6.
18.
HalstensonC., MacresM., KatzS.A.Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta.Clin Pharmacol Ther1991; 50: 702–12.
19.
MacdougallI.C., JonesJ.M., RobinsonM.I.Subcutaneous erythropoietin therapy: Comparison of three different sites of injection.Contrib Nephrol1991; 88: 152–6.
20.
BargmanJ.M., JonesJ.E., PetroJ.M.The pharmacokinetics of intraperitoneal erythropoietin administered undiluted or diluted in dialysate.Perit Dial Int1992; 12: 369–72.
21.
FrenkenL.A.M., StruijkD.K., CoppensP.J.W.Intraperitoneal administration of recombinant human erythropoietin.Perit Dial Int1992; 12: 378–83.
22.
LaiK.N., LuiS.F., LeungJ.C.K.Effect of subcutaneous and intraperitoneal administration of recombinant human erythropoietin on blood pressure and vasoactive hormones in patients on continuous ambulatory peritoneal dialysis.Nephron1991; 57: 394–400.
23.
NasuT., MituiH., ShinoharaY.Effect of erythropoietin in continuous ambulatory peritoneal dialysis patients: Comparison between intravenous and intraperitoneal administration.Perit Dial Int1992; 12: 373–7.
24.
NissensonA.R.Erythropoietin and peritoneal dialysis: The efficacy of intraperitoneal dosing.Perit Dial Int1992; 12: 350–2.
25.
FrenkenL.A.M., Van LierH.J.J., GerlagP.G.G.Assessment of pain after subcutaneous injection of erythropoietin in patients receiving haemodialysis.Br Med J1992; 303: 288.
26.
GranollerasC., LeskopfW., ShaldonS., FourcadeJ.Experience of pain after subcutaneous administration of different preparations of recombinant human erythropoietin: A randomized, double-blind crossover study.Clin Nephrol1991; 36: 294–8.
27.
AbrahamP.A., St PeterW.L., Redic-KiiiK.A., HalstensonC.E.Controversies in determination of epoetin (recombinant human erythropoietin) dosages.Clin Pharmacokinet1992; 22: 409–15.
28.
BesarabA., FlahartyK.K., ErslevA.E.Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: The case for subcutaneous administration.J Am Soc Nephrol1991; 2: 1405–16.
29.
MacdougallI.C.How to get the best out of r-HuEPO.Nephrol Dial Transplant1995; 10(Suppl 2): 85–91.
30.
ZimmermanS.W., JohnsonC.A.Erythropoietin use in peritoneal dialysis patients.Am J Kidney Dis1991; 18(Suppl 1): 38–41.
31.
ChenglK.P., CyC, ChanM.K.Correction of anemia in patients on continuous ambulatory peritoneal dialysis with subcutaneous recombinant erythropoietin twice a week: A long-term study.Clin Nephrol1991; 35: 207–12.
32.
EiseleG., BailieG.R., ClementC., WongE.Erythropoietin in continuous ambulatory peritoneal dialysis: Experience with subcutaneous administration.Perit Dial Int1992; 12: 34–6.
33.
HughesR.T., CotesP.M., PippardM.J.Subcutaneous administration of recombinant human erythropoietin to subjects on continuous ambulatory peritoneal dialysis: An erythrokinetic assessment.Br J Haematol1990; 75: 268–73.
34.
LuiS.F., LawC.B., TingS.M.Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis.Clin Nephrol1991; 36: 246–51.
35.
MacdougallI.C., DaviesM.E., Hut tonR.D.The treatment of renal anaemia in CAPD patients with recombinant human erythropoietin.Nephrol Dial Transplant1990; 5: 950–5.
36.
Sinai-TriemanL., SaluskyI.B., FineR.N.Use of subcutaneous recombinant human erythropoietin in children undergoing continuous cyclic peritoneal dialysis.J Pediatr1989; 114: 550–4.
37.
SteinhauerH.B., Lubrich-BirknerI., DreylingK.W., SchollmeyerP.Effect of human recombinant erythropoietin on anaemia and dialysis efficiency in patients undergoing continuous ambulatory peritoneal dialysis.Eur J Clin Invest1991; 21: 47–52.
38.
StevensJ.M., AuerJ., StrongC.A.Stepwise correction of anaemia by subcutaneous administration of human recombinant erythropoietin in patients with chronic renal failure maintained by continuous ambulatory peritoneal dialysis.Nephrol Dial Transplant1991; 6: 487–94.
39.
SalehA., KraneN.K., CaballeroM., StarksE.Once weekly subcutaneous erythropoietin is an effective maintenance therapy in the treatment of anemia of end stage renal disease in patients on CAPD. In: KhannaR., NolphK.D., ProwantB.F., TwardowskiZ.J., OreopoulosD.G. eds. Advances in peritoneal dialysis.Toronto: Peritoneal Dialysis Bulletin Inc., 1991; 7: 288–91.
40.
FallerB., SlingeneyerA., WallerM.Daily subcutaneous administration of recombinant human erythropoietin (rh-EPO) in peritoneal dialysis patients: A European dose-response study.Clin Nephrol1993; 40: 168–75.
41.
NomotoY., KawaguchiY., KubotaM.A multicenter study with once a week or once every two weeks high dose subcutaneous administration of recombinant human erythropoietin in continuous ambulatory peritoneal dialysis.Perit Dial Int1994; 14: 56–60.
42.
NissensonA.R., KorbetS., FaberM.Multicenter trial of erythropoietin in patients on peritoneal dialysis.J Am Soc Nephrol1995; 5: 1517–29.
43.
BárányP., ClyneN., HylanderB.Subcutaneous epoetin beta in renal anemia: An open multicenter dose titration study of patients on continuous peritoneal dialysis.Perit Dial Int1995; 15: 54–60.
44.
HörlW.H.Optimal route of administration of erythropoietin in chronic renal failure patients: Intravenous versus subcutaneous.Acta Haematol1992; 87(Suppl 1): 16–19.
45.
DrüekeT.B.R HuEPO hyporesponsiveness -who and why?NephrolDial Transplant1995; 10(Suppl 2): 62–8.
46.
DanielsonB.R-HuEPO hyporesponsiveness -who and why?Nephrol Dial Transplant1995; 10(Suppl 2): 69–73.
47.
RajaR., BloomE., GoldsteinM., JohnsonR.Erythro poietin with oral iron in peritoneal and hemodialysis patients -a comparison in an inner city population.ASAIO J1993; 39: M578–M580.
48.
BirgegårdG.Erythropoiesis and inflammation.Contrib Nephrol1989; 76: 330–41.
49.
MuirheadN., HodsmanA.B., HollombyD.J., CordyP.E.T he role of aluminum and parathyroid hormone in erythropoietin resistance in haemodialysis patients.Nephrol Dial Transplant1991; 6: 342–5.
50.
RaoD.S., ShihM-S, MohiniR.Effect of serum parathyroid hormone and bone marrow fibrosis on the response of erythropoietin in uremia.N Engl J Med1993; 328: 171–5.
51.
SundalE., KaeserU.Correction of anemia of chronic renal failure with recombinant human erythropoietin: Safety and efficacy of one year's treatment in a European multicentre study of 150 haemodialysis -dependent patients.MephrolDial Transplant1989; 4: 979–87.
52.
MannJ.F.E.Hypertension and cardiovascular effects-Iong-term safety and potentiallong-term benefits of r-HuEPO.Nephrol Dial Transplant1995; 10(Suppl 2): 80–4.
53.
WallsJ.Haemoglobin is more better?Nephrol Dial Transplant1995; 10(Suppl 2): 56–61.
54.
KorbetS.M., VoneshE.F., FiranekC.A.The effect of hematocrit on peritoneal transport.Am J Kidney Dis1995; 18: 573–8.
55.
HutchisonA.J., OfsthunN.J., HowarthD., GokalR.The effect of haemoglobin concentration on peritoneal mass transfer and drain volumes in continuous ambulatory peritoneal dialysis.Perit Dial Int1992; 12: 230–3.
56.
TaylorJ.E., MactierR.A., HendersonI.S.Dialysis efficiency in continuous ambulatory peritoneal dialysis patients treated with erythropoietin.Perit Dial Int1992; 12: 221–6.
57.
HeimbürgerO., BaranyP., TranæusA.Peritoneal transport and EPO.Dialysis and Transplant1994; 23: 130–6.
58.
Canadian Erythropoietin Study Group.Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis.Br Med J1990; 300: 573–8.
59.
McMahonL.P., JohnsJ.A., McKenzieA.Haemodynamic changes and physical performance at comparative levels of haemoglobin after long-term treatment with recombinant erythropoietin.Nephrol Dial Transplant1992; 7: 1199–206.
60.
McMahonL.P., DawbornJ.K.Subjective quality of life assessment in hemodialysis patients at different levels of hemoglobin following use of recombinant human erythropoietin.Am J Nephrol1992; 12: 162–9.
61.
BárányP., SvedenhagJ., FreyschussU., BergströmJ.Physiological effects of correcting anemia in hemodialysis patients to a normal hemoglobin concentration (Abstract).Clinical Investigator1994; 72: 5B13.
62.
AuerJ., SimonG., StevensJ.Quality of life improvements in CAPD patients treated with subcutaneously administered erythropoietin for anemia.Perit Dial Int1992; 12: 40–2.
63.
EkblomB., BerglundB.Effect of erythropoietin administration on maximal aerobic power in man.Scand J Med Sci Sports1991; 1: 88–93.
64.
BárányP., FreyschussU., PetterssonE., BergströmJ.Treatment of the anaemia in haemodialysis patients with erythropoietin: Long-term effects on exercise capacity.Clin Sci1993; 84: 441–7.
